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Abstract
In mouse models of chronic inflammatory diseases, Natural Killer (NK) cells can play an immunoregulatory role by
eliminating chronically activated leukocytes. Indirect evidence suggests that NK cells may also be immunoregulatory in
humans. Two subsets of human NK cells can be phenotypically distinguished as CD16
+CD56
dim and CD16
dim/2CD56
bright.A n
expansion in the CD56
bright NK cell subset has been associated with clinical responses to therapy in various autoimmune
diseases, suggesting an immunoregulatory role for this subset in vivo. Here we compared the regulation of activated human
CD4
+ T cells by CD56
dim and CD56
bright autologous NK cells in vitro. Both subsets efficiently killed activated, but not resting,
CD4
+ T cells. The activating receptor NKG2D, as well as the integrin LFA-1 and the TRAIL pathway, played important roles in
this process. Degranulation by NK cells towards activated CD4
+ T cells was enhanced by IL-2, IL-15, IL-12+IL-18 and IFN-a.
Interestingly, IL-7 and IL-21 stimulated degranulation by CD56
bright NK cells but not by CD56
dim NK cells. NK cell killing of
activated CD4
+ T cells was suppressed by HLA-E on CD4
+ T cells, as blocking the interaction between HLA-E and the
inhibitory CD94/NKG2A NK cell receptor enhanced NK cell degranulation. This study provides new insight into CD56
dim and
CD56
bright NK cell-mediated elimination of activated autologous CD4
+ T cells, which potentially may provide an opportunity
for therapeutic treatment of chronic inflammation.
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Introduction
Natural killer (NK) cells are a critical component of the innate
immune response, and were initially described as lymphoid cells
that exhibit a ‘‘natural cytotoxicity’’ against virally infected cells
and tumor cells without prior activation [1,2]. The ability of NK
cells to distinguish between potential target cells and healthy cells
is regulated by an integration of signals derived from a complex
repertoire of activating and inhibitory receptors [3]. Activating
NK cell receptors, such as NKG2D and the natural cytotoxicity
receptors (NCR), typically recognize ligands that are stress-
induced, pathogen-derived or tumor-associated. In contrast,
inhibitory receptors such as the inhibitory killer cell immunoglob-
ulin-like receptors (iKIR) and the CD94/NKG2A heterodimer,
monitor the absence of MHC class I proteins, which are normally
expressed on healthy cells but can be downregulated upon
infection or cellular stress. This ability to detect downregulation
of MHC class I molecules is referred to as ‘‘missing-self’’ detection
[4].
Studies have shown that depletion of NK cells can strongly
exacerbate disease in mouse models of chronic inflammation,
including myelin oligodendrocyte glycoprotein (MOG)-induced
experimental autoimmune encephalomyelitis (EAE) [5], a model
of multiple sclerosis (MS), as well as Staphylococcus aureus- and
collagen-induced arthritis (CIA) [6,7]. NK cell immunoregulatory
activity was perforin-dependent in both a CD4
+ Tc e l lt r a n s f e r
model of colitis [8] as well as in EAE [9] and CIA [7], suggesting
that NK cell cytolytic activity plays an important immunoregu-
latory role in vivo. Recent studies in different EAE models have
shown that activated CD4+ T cells are protected from NK cell
lysis by their expression of Qa-1, the mouse homolog of the non-
classical MHC class Ib molecule HLA-E, which binds the
inhibitory receptor CD94/NKG2A on NK cells. Interruption of
the interaction between Qa-1 and CD94/NKG2A through a
genetic mutation, or administration of a blocking anti-NKG2A
F(ab)’2 fragment, resulted in potent NK cell-mediated elimination
of pathogenic CD4
+ T cells and amelioration of EAE [9], and
was associated with decreased infiltration of MOG-specific T cells
and reduced microglia activation in the central nervous system
[10]. Furthermore, a recent study has shown that NK cells
ameliorate CIA by lysis of two subsets of disease-inducing CD4
+
T cells: follicular helper (Tfh) and Th17 cells. Blocking with an
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31959anti-NKG2A F(ab)’2 fragment lead to enhanced lysis of Tfh and
Th17 cells by NK cells, and disease arrest [7]. These studies
suggest that NK cells can regulate established immune responses
both locally, at inflammatory sites, as well as systemically, in
lymphoid organs.
Human NK cells comprise approximately 10% of all peripheral
blood lymphocytes and can be divided into two subsets based on
surface expression of CD56 (NCAM) and CD16 (FccRIII). In
peripheral blood, approximately 90% of circulating NK cells are
CD56
dimCD16
+, whereas the remaining 10% are CD56
bright
CD16
dim/2 [11]. In contrast, CD56
bright NK cells are abundant
in secondary lymphoid organs (particularly in tonsils and lymph
nodes), and NK cells with a CD56
brightKIR
2NKG2A
+ phenotype
accumulate in inflamed tissues, such as in synovial fluid and tissue in
rheumatoid arthritis, psoriatic skin plaques, and in spinal fluid and
brain lesions in multiple sclerosis [12,13], diseases where effector
CD4
+ T cells play an important role in disease pathogenesis.
Indirect evidence suggests that human NK cells may have an
immunoregulatory function in controlling activated immune cells.
Patients with familial hemophagocytic lymphohistiocytosis (FHL),
who suffer from impaired cell cytolytic activity, develop hyper-
inflammation and abnormal activation and infiltration of macro-
phages and T cells [14]. In patients with relapse-remitting (RR)-
MS, it has been shown that NK cell activity drops prior to clinical
relapse, and that clinical remission is preceded by an increase in
NK cell activity [15]. Furthermore, an expansion of CD56
bright
NK cells correlates with clinical responses to therapy in RR-MS
patients treated with IFN-b, Linomide, Zenapax or methyl-
prednisolone [16,17]. These studies imply the involvement of NK
cells, and particularly the CD56
bright subset, in regulating chronic
inflammation.
The mechanism of action of immunoregulatory NK cells in
human autoimmune disease in vivo remains unclear. Numerous
studies have demonstrated NK cell-mediated killing of activated T
cells [18–21], dendritic cells (DCs) [22,23], macrophages [24] and
microglia [25] in vitro. The activating NK cell receptor NKG2D
has been shown to be an important receptor stimulating NK cell-
mediated elimination of activated CD4
+ T cells in vitro [20,21].
However, the role of other receptors and ligands is unclear.
Furthermore, most in vitro studies of human NK cell-mediated
cytotoxicity have not distinguished between the CD56
dim and
CD56
bright subsets of NK cells, which is important in relation to
understanding NK cell-mediated clearance of pathogenic cells in
vivo, where these subsets preferentially localize in different tissues.
The purpose of this study was therefore to further examine the
regulation of autologous activated CD4
+ T cells by CD56
dim and
CD56
bright NK cells.
Results
Activated NK cells degranulate in response to activated,
but not resting, autologous CD4
+ T cells
We characterized the regulation of activated CD4
+ T cells by
NK cells. It has previously been shown that in vitro activated, but
not resting, CD4
+ T cells are susceptible to NK cell-mediated lysis
in vitro [20,21]. To further characterize this process, untouched
CD4
+ T cells and NK cells were purified from blood of healthy
donors by negative selection, and were cultured separately for 4
days. NK cells were activated with 200 IU/mL IL-2. CD3
2
CD56
dim and CD56
bright NK cell were distinguished by flow
cytometry based on differential expression of CD16 and CD56, as
shown in Fig. 1A (the full gating strategy is presented in Fig. S1).
CD4
+ T cells were activated with anti-CD3 and anti-CD28
Dynabeads (with the addition of 10 mM propionate on day 3), and
resting CD4
+ T cells were cultured in media alone for 4 days.
Activation of CD4
+ T cells was confirmed by upregulation of
CD69, as shown in Fig. 1B for a representative donor.
After 4 days of activation, autologous CD4
+ T cells and NK cells
were co-cultured at an E:T ratio of 1:1 for 4 hours. NK cell
degranulation was assessed by the addition of FITC-conjugated
anti-CD107a (lysosomal-associated membrane protein (LAMP)-1)
and anti-CD107b (LAMP-2) antibodies during co-culture, as
CD107a and CD107b are expressed on the surface of cytolytic
granules in association with granule exocytosis, a prerequisite for
NK cell-mediated cytotoxicity. The expression of CD107a/b on the
surfaceofcytotoxiccellsisa well-validatedmarkerfordegranulation
and correlates well with specific lysis of the target cell [26,27]. As
shown in Fig. 1C, both subsets of IL-2 activated NK cells
(CD56
bright and CD56
dim) degranulated in response to activated,
but not resting, CD4
+ T cells. The extent of degranulation varied
between donors, butas shown in Fig.1D, an average of 23%63.4%
CD56
dim NK cells degranulated in response to activated CD4
+ T
cells, compared to 39%67.6% CD56
bright NK cells. We verified
that the degranulation of NK cells corresponded with the killing of
CD4
+ T cells. Activated CD4
+ T cells were labeled with
51Cr, and
co-cultured with sorted CD56
dim or CD56
bright NK cells. As shown
in Fig. 1E, both subsets of IL-2-activated NK cells efficiently killed
activated CD4
+ T cells, whereas resting NK cells did not kill
activated CD4
+ T cells. Activated NK cells did not kill resting CD4
+
T cells (data not shown). This confirms that IL-2 activated CD56
dim
andCD56
brightNK cells both degranulate and killactivated, butnot
resting, autologous CD4
+ T cells.
Cytokines enhance degranulation of CD56
dim and
CD56
bright NK cells
In a chronic inflammatory environment, such as in the
synovium of an inflamed RA joint, NK cells are exposed to a
complex combination of cytokines and chemokines. We therefore
addressed the effect of different cytokines on NK cell-mediated
cytotoxicity towards activated CD4
+ T cells. IL-2 and IL-15 are
‘‘classical’’ NK stimuli, that are essential for NK cell development
and homeostasis [28], and enhance NK cell proliferation,
cytotoxicity and IFN-c secretion [29,30]. Other cytokines such
as type I interferons or IL-12+IL-18 are known to promote IFN-c
production [31], proliferation [32] and Th1 polarization by NK
cells [33]. Many studies on NK cell-mediated cytotoxicity in vitro
do not distinguish between the CD56
dim and CD56
bright
populations, and we therefore investigated how cytokines stimulate
the two NK cell subsets in our experimental setting. As shown in
Fig. 2A, CD56
dim NK cells only degranulated in response to
activated CD4
+ T cells when stimulated with IL-2, IL-15, IL-18,
IL-12+IL-18 or IFN-a. Culture with IL-4, IL-7, IL-9, IL-12 alone
or IL-21 did not lead to CD56
dim NK cell degranulation.
We observed that several cytokines enhanced the degranulation of
CD56
bright NK cells towards activated CD4
+Tc e l l s :I L - 2 ,I L - 7 ,I L - 1 5 ,
IL-21, IL-12, IL-18, IL-12+IL-18 and IFN-a. In contrast, IL-4 and IL-
9 did not affect the degranulation of CD56
bright NK cells towards
activated CD4
+ T cells. These results suggest that numerous cytokines
stimulate the degranulation of both NK cell subsets towards activated
CD4
+ T cells: IL-2, IL-15, IL-12+IL-18 and IFN-a.F u r t h e r m o r e ,
CD56
bright NK cells are also activated by IL-7 and IL-21.
NK cell degranulation towards activated CD4
+ T cells is
primarily controlled by NKG2D, NKp46, LFA-1 and NKG2A
in both NK cell subsets
NK cell-mediated lysis of a target cell is a result of an integration
of signals received through activating and inhibitory NK cell
Cytotoxicity of CD56
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31959Figure 1. Activated NK cells kill activated, but not resting, CD4
+ T cells. (A) Representative gating strategy. NK cells were defined as viable,
CD3
2 singlets. NK cell subsets were defined based on expression of CD16 and CD56. (B) Activation of CD4
+ T cells was confirmed by CD69
upregulation. CD4
+ T cells were activated for 4 days with anti-CD3+anti-CD28 Dynabeads (propionate was added on day 3). Resting CD4
+ T cells were
unstimulated in media for 4 days. (C–D) NK cells were cultured for 4 days in IL-2, and CD4
+ T cells were activated as described. Resting CD4
+ T cells
were unstimulated for 4 days in culture. Autologous NK cells and CD4
+ T cells were co-cultured at an E:T ratio of 1:1 for 4 hours with FITC-conjugated
anti-CD107a+anti-CD107b mAb. Flow cytometry was performed to determine CD107a/b expression on NK cell subsets. Data shown in (C) are for a
representative donor, (D) are for n=9. Data represent mean 6 SEM. * P,0.05; *** P,0.001. (E) Sorted CD56
dim (%/&) and CD56
bright (#/N) NK cells
were cultured in media (%/#) or IL-2 (&/N) for 4 days, and co-cultured with
51Cr-labeled activated CD4
+ T cells in a
51Cr-release assay. Experiment
shown is representative of n=3.
doi:10.1371/journal.pone.0031959.g001
Figure 2. CD56
bright NK cells have a higher cytotoxic potential towards activated CD4
+ T cells. Autologous NK cells and CD4
+ T cells were
isolated, and CD4
+ T cells were activated for 4 days as described. NK cells were activated as indicated: 200 IU/mL IL-2, 25 ng/mL IL-4, 25 ng/mL IL-7,
25 ng/mL IL-9, 5 ug/mL IL-15, 100 ug/mL IL-21, 50 ug/mL IL-12, 0.25 mg/mL IL-18 or 100 U/mL IFN-aA. NK cells and CD4
+ T cells were co-cultured for
4 hours with FITC-conjugated anti-CD107a+anti-CD107b antibodies. Flow cytometry was performed to determine degranulation of (A) CD56
dim NK
cells and (B) CD56
bright NK cells. Data represent mean 6 SEM of n$4 experiments. Statistical significance is calculated in comparison to resting NK
cells (media) co-cultured with activated CD4
+ T cells. * P,0.05, ** P,0.005, *** P,0.001.
doi:10.1371/journal.pone.0031959.g002
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corresponding ligands on CD4
+ T cells, are involved in the
recognition and lysis of activated CD4
+ T cells. The expression of
potential ligands on activated CD4
+ T cells was analyzed and
compared to expression on CD4
+ T cells cultured in media alone.
For all ligands studied, expression on freshly isolated CD4
+ T cells
was identical to the expression found after 4 days in media (data
not shown). We also studied the expression of the corresponding
NK cell receptors on IL-2 activated NK cells compared to resting
NK cells, and assessed whether blocking the interaction between
the ligand and its corresponding receptor on NK cells affected
degranulation. NK cell degranulation was not altered by the
presence of an isotype-matched control Ig during co-culture, and
we verified that the addition of antibodies to NK cells alone did
not result in NK cell degranulation (data not shown).
As shown in Fig. 3A, the activating receptor NKG2D plays a
major role in NK cell-mediated lysis of activated CD4
+ T cells. It
has previously been shown that activated CD4
+ T cells upregulate
NKG2D ligands and become susceptible to NK cell-mediated lysis
via NKG2D [20,21]. As shown in Fig. 3A for a representative
donor, we confirmed that activated CD4
+ T cells express high
levels of the NKG2D ligands MIC-A, MIC-B and ULBP-1. The
addition of an anti-NKG2D neutralizing antibody reduced
degranulation of CD56
dim and CD56
bright NK cells by
70%62.7% and 63.4%65.2%, respectively, relative to an
isotype-matched control Ig. This confirms that NKG2D is an
important activating receptor in NK cell-mediated lysis of
autologous activated CD4
+ T cells.
We found that activated CD4
+ T cells upregulate CD155
(poliovirus receptor, PVR), a ligand for the activating NK cell
receptor DNAM-1. We could not detect expression of CD112
(poliovirus-related receptor 2, PRR2), another DNAM-1 ligand,
on CD4
+ T cells. Blocking DNAM-1, however, did not affect
degranulation of either NK cell subset towards activated CD4
+ T
cells (Fig. 3A). It has been shown that two additional NK receptors
can interact with CD155: TIGIT, an inhibitory receptor expressed
by all NK cells [34], and CD96 (TACTILE), which promotes NK
cell adhesion to target cells expressing CD155 [35]. Despite the
expression of CD155 on activated CD4
+ T cells, blocking CD96
or TIGIT did not affect the degranulation of either subset of NK
cells (Fig. S2A).
Adding a neutralizing anti-NKp46 antibody to the co-culture
significantly reduced degranulation of CD56
dim NK cells by
25.3%63.6%, and of CD56
bright NK cells by 38.2%66.4%
(Fig. 3A). Blocking the NCRs NKp30 or NKp44 did not affect
degranulation (Fig. S2B). Although we detected CD48, the ligand
for the activating NK cell receptor 2B4, on both resting and
activated CD4
+ T cells, we could not find a role for 2B4 in NK cell
killing of activated CD4
+ T cells (Fig. S2B).
Efficient cytolytic function of NK cells and cytotoxic CD8
+ T
cells is dependent on adhesion of the b2 integrin LFA-1 to CD54
(intercellular adhesion molecule 1, ICAM-1) on target cells [36].
Resting CD4
+ T cells constitutively express CD54 (Fig. 3A), and
activated CD4
+ T cells further upregulate CD54 expression.
Blocking LFA-1 in our co-culture significantly reduced degranu-
lation of CD56
dim NK cells by 66.6%61.7%, and of CD56
bright
NK cells by 65.4%67.5%.
Resting CD4
+ T cells express low levels of the non-classical
MHC class I molecule HLA-E (Fig. 3B), which binds the
inhibitory CD94/NKG2A receptor on NK cells, whereas
activated CD4
+ T cells upregulate HLA-E expression. Blocking
the interaction between HLA-E and the inhibitory receptor
CD94/NKG2A with an anti-NKG2A mAb resulted in an average
31.3%65.3% increase in the percentage of degranulating
CD56
dim NK cells, and an almost two-fold (96.6%636.9%)
increase in degranulation of CD56
bright NK cells. The inhibitory
receptor CD94/NKG2A thus plays a major role in NK cell-
mediated lysis of activated CD4
+ T cells. Although we found that
activated CD4
+ T cells upregulate expression of HLA-G, a ligand
for the inhibitory NK cell receptor LIR-1, blocking LIR-1 did not
affect the degranulation of NK cells (Fig. S2C).
It has previously been shown that simultaneous engagement of
NKG2D, 2B4 and LFA-1 on NK cells defines a minimum
requirement for target cell lysis by resting NK cells [37], and that
these receptors act synergistically in mediating NK cell cytotox-
icity. As shown in Fig. 4A and 4B for CD56
dim and CD56
bright NK
cells, respectively, we found that LFA-1 and NKG2D act
synergistically in inducing NK cell degranulation, as blocking
both receptors completely inhibited the degranulation of NK cells.
CD56
dim NK cells express the inhibitory CD94/NKG2A
receptor in a heterogeneous, stochastic manner, and we
investigated whether NK cells expressing CD94/NKG2A prefer-
entially degranulate in response to activated CD4
+ T cells. As
shown in Fig. 4C, we found that an average of 35.1%65.9%
CD56
dimNKG2A
+ NK cells degranulate, compared to
17.8%64.2% CD56
dimNKG2A
2 NK cells. A higher level of
cytotoxic function among NKG2A
+ NK cells, compared to
NKG2A
2 NK cells, has been observed previously [9,38]. Such
an analysis cannot be carried out on CD56
bright NK cells as these
are all NKG2A
+.
NK cells are able to kill target cells by means other than
perforin-mediated cytotoxicity, and we addressed whether NK
cells eliminate activated CD4
+ T cells via the TNF-related
apoptosis-inducing ligand (TRAIL) pathway, as this pathway has
been implicated in NK cell-mediated elimination of immune cells
both in vivo and in vitro [39,40]. TRAIL can interact with five death
receptors (DR), three of which are decoy receptors (DR1, DR2
and DR3) that block TRAIL-induced apoptosis, and two (DR4
and DR5) that induce apoptosis in target cells [40]. As shown in
Fig. 5A, we found that activated, but not resting, CD4
+ T cells
express both DR4 and DR5. We confirmed that both subsets of
NK cells express TRAIL after activation with IL-2 (Fig. 5B), and
TRAIL expression is highest in the CD56
bright subset. As shown in
Fig. 5C, blocking TRAIL with a neutralizing antibody significantly
inhibited killing of activated CD4
+ T cells by CD56
bright NK cells,
but had no effect on killing by CD56
dim NK cells, relative to an
isotype-matched control Ig. This suggests a role for TRAIL, albeit
minor, in CD56
bright NK cell-mediated killing of autologous
activated CD4
+ T cells in vitro.
Discussion
It is becoming increasingly appreciated that NK cells may play
an immunoregulatory role in limiting autoimmune responses.
Elimination of chronically activated immune cells is one
mechanism by which NK cells perform this immunoregulatory
role, and in this study we have demonstrated that activated NK
cells degranulate and kill activated, but not resting, autologous
CD4
+ T cells. We found that both subsets of human NK cells,
CD56
dim and CD56
bright, kill activated CD4
+ T cells. Although
CD56
dim NK cells are typically cited as being the more cytotoxic
subset due to higher levels of perforin, granzymes and cytolytic
granules [41], other studies have shown that following activation,
CD56
bright NK cells are equally, if not more, cytotoxic [42,43].
Our study confirms that both subsets are equally cytotoxic
following IL-2 activation.
In a chronic inflammatory environment, NK cells will be
exposed to a plethora of cytokines, and we studied the effect of
Cytotoxicity of CD56
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classical NK cell stimuli, and are essential for NK cell development
and homeostasis [28]. These cytokines, as well as type I interferons
(IFN-a) and IL-12+IL-18, are known to enhance NK cell
proliferation, cytotoxicity and IFN-c secretion [29–33]. We found
that IL-2, IL-15, IL-12+IL-18 and IFN-a enhanced degranulation
of both subsets of NK cells towards activated CD4
+ T cells.
Furthermore, we found that IL-7 and IL-21 stimulated degran-
ulation of CD56
bright, but not CD56
dim, NK cells. The IL-7
receptor (IL-7Ra) is only expressed by CD56
bright NK cells [30],
and IL-7 promotes survival and enhances cytotoxicity of these cells
[44]. The IL-21 receptor is expressed by all NK cells in the blood,
and IL-21 stimulates NK cell survival, cytotoxicity and IFN-c
secretion [30]. The synovial fluid of RA patients has been found to
contain high levels of IL-12 [45], IL-18 [46], IL-15 [47], IL-7 [48]
and IL-21 [49], and cytokines such as IL-12, IL-18 and IFN-a are
produced by activated DCs and macrophages and have also been
implicated in chronic inflammation [30], making it plausible that
NK cells, in a chronic inflammatory setting, can become activated
by several cytokines. It is interesting to highlight that regardless of
how NK cells were activated, the same activating and inhibitory
receptors controlled degranulation of NK cells in response to
activated autologous CD4
+ T cells (data not shown).
We found that NKG2D, LFA-1 and NKp46 are involved in NK
cell degranulation towards activated CD4
+ T cells in both
CD56
dim and CD56
bright NK cells. We detected high levels of
several NKG2D ligands on activated CD4
+ T cells, and numerous
studies have shown that T cells upregulate single or numerous
NKG2D ligands and become susceptible to NKG2D-mediated
lysis following activation with various stimuli in vitro [20,21,50,51].
Discrepancies as to which NKG2D ligands are upregulated, as
well as expression levels, are likely a result of how CD4
+ T cells are
activated as well as the time frame for analysis, as we found that
ligand expression varied between donors but was highest after 4
days (data not shown). In addition, MICA and MICB genes are
highly polymorophic [52], so different allelic variants may behave
differently. NKG2D has also been implicated as an important
receptor in NK cell-mediated lysis of macrophages [24], tumor
cells [53] and microglia [25] as well as regulatory T cells [19].
We show that the lysis of activated CD4
+ T cells by NK cells is
dependent on engagement of the b2 integrin LFA-1. Adhesion
through LFA-1 is a requirement of efficient target cell lysis by NK
cells and cytotoxic CD8
+ T cells [36], and engagement of LFA-1
not only mediates adhesion, but can also activate NK cells [54].
We found that NKG2D and LFA-1 act synergistically in
mediating degranulation, as it was necessary to block both
receptors simultaneously to completely inhibit degranulation of
NK cells. Simultaneous engagement of NKG2D, 2B4 and LFA-1
has previously been shown to define a minimum requirement for
target cell lysis by resting NK cells [37].
The activating receptor DNAM-1 has been implicated in NK
cell-mediated lysis of DCs [22] and myeloma cells [53]. Despite
the expression of one ligand for DNAM-1 on activated CD4
+ T
cells (CD155 (poliovirus receptor (PVR)), but not CD112 (Nectin-
2)), blocking DNAM-1 did not affect degranulation of NK cells.
CD155 has also been shown to interact with the NK cell receptors
TIGIT (an inhibitory receptor that binds CD155 with a higher
affinity than DNAM-1) [34] and CD96 (TACTILE, which
Figure 4. NKG2D and LFA-1 act synergistically in mediating NK cell degranulation. NK and CD4
+ T cells were activated for 4 days in vitro as
described, and co-cultured for 4 hours with FITC conjugated anti-CD107a+anti-CD107b mAbs. 10 ug/mL blocking antibodies (or relevant isotype-
matched control Ig) were added where indicated. Flow cytometry was performed to assess degranulation of (A) CD56
dim and (B) CD56
bright NK cells.
(C) CD56
dim NK cells were gated based on surface expression of CD94/NKG2A, and degranulation of each subset was evaluated. * P,0.05.
doi:10.1371/journal.pone.0031959.g004
Figure 3. Multiple receptors and ligands are involved in NK cell-mediated lysis of activated CD4
+ T cells. Role of (A) activating and (B)
inhibitory NK receptors in NK cell degranulation. Left column: representative histograms (of n$3) for surface expression of ligands on activated (thick
black line) and resting CD4
+ T cells (thin black line). Isotype-matched control Ig are represented by dashed line (activated CD4
+ T) and filled histogram
(resting CD4
+ T). Middle- and right column: NK and CD4
+ T cells were activated for 4 days in vitro as described, and co-cultured for 4 hours with
10 ug/mL mAb (or relevant isotype-matched control Ig). Degranulation is shown for CD56
dim (middle column) and CD56
bright (right column) NK cells.
Representative histograms of surface expression of receptors on activated (thick black line) and resting NK cells (thin black line). Isotype-matched
control Ig are represented by dashed line (activated NK) and filled histogram (resting NK). * P,0.05, ** P,0.005, *** P,0.001. (C) Sorted IL-2-activated
CD56
dim and CD56
bright NK cells were co-cultured with
51Cr-labeled activated CD4
+ T cells in a
51Cr-release assay with human IgG4 isotype control (N)
or anti-NKG2A mAb (#). Data represents n=3 experiments.
doi:10.1371/journal.pone.0031959.g003
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However, blocking CD96 or TIGIT did not affect degranulation
of either NK cell subset. A previous study has shown that
monocyte-derived reactive oxygen species (ROS) is required for
optimal expression of CD155 on activated T cells [55], and the
expression of CD155 on activated CD4
+ T cells in our
experiments may thus be below a threshold necessary to induce
a signal via DNAM-1, CD96 or TIGIT.
NK cells can also induce target cell death by membrane-bound
and secreted TNF-related apoptosis-inducing ligand (TRAIL),
which transduces apoptotic signals upon binding death receptors
DR4 (TRAIL-R1) and DR5 (TRAIL-R2) [40]. We found that
activated CD4
+ T cells upregulate both DR4 and DR5 and
become susceptible to TRAIL-mediated lysis. It has been shown
that NK cells eliminate immature DCs in vivo via TRAIL [39], and
our studies indicate a minor role for TRAIL in CD56
bright NK
cell-mediated killing of autologous activated CD4
+ T cells in vitro.
Expression of the non-classical MHC class I molecule HLA-E
has been shown to protect DCs [38] and CD4
+ T cells [18] from
NK cell-mediated lysis by interactions with the inhibitory receptor
CD94/NKG2A. We found that activated CD4
+ T cells upregulate
HLA-E and were protected from NK cell-mediated lysis, as the
addition of an anti-NKG2A antibody significantly enhanced
killing of activated CD4
+ T cells. Blocking NKG2A had a greater
effect on enhancing degranulation of CD56
bright NK cells, which is
not surprising as this subset constitutively expresses higher levels of
NKG2A, whereas only approximately half of CD56
dim NK cells
express NKG2A, and at a lower density.
It is interesting why healthy T cells, upon activation, transiently
upregulate ligands for NK cell receptors that render them
susceptible to NK cell-mediated lysis. It has been proposed that
NK cells, during the course of a normal immune response, reduce
potentially excessive inflammation by eliminating some activated
immune cells [56]. The susceptibility of a cell to NK cell-mediated
lysis depends on a balance between ligands expressed for activating
and inhibitory NK cell receptors. Interestingly, resting DCs and
microglia are susceptible to NK cell-mediated cytotoxicity [57,58],
whereas activation of these cells upregulates MHC class I
molecules and confers resistance to lysis [25]. On the contrary,
resting monocytes, monocyte-derived macrophages and T cells are
protected from NK cell-mediated cytotoxicity, but upon activation
these cells upregulate NKG2D ligands and become susceptible to
NK cell lysis [9,18,25,59,60]. We found that resting CD4
+ T cells
expressed much lower levels of all MHC class I molecules
compared to activated CD4
+ T cells (Fig. S3), yet resting CD4
+ T
cells were not susceptible to NK cell-mediated lysis, and blocking
with an anti-HLA class I antibody did not result in NK cell
degranulation. The lack of activating receptor ligands likely
explains why resting CD4
+ T cells are protected from NK cell
cytotoxicity, regardless of expression of MHC class I molecules.
The specificity of NKG2D ligand expression to activated CD4
+ T
cells highlights why unleashing NK cells by masking an inhibitory
receptor such as NKG2A presents an interesting therapeutic
opportunity to treat chronic inflammation compared to current
strategies, as it may allow for lysis of a small subpopulation of
activated, potentially pathogenic CD4
+ T cells, while leaving the
remaining T cell repertoire intact. Indeed, in a mouse model of
RA, CIA, it has recently been shown that blocking NKG2A
specifically leads to NK cell-mediated lysis of pathogenic Tfh and
Th17 cells, and thus abrogation of disease development [7].
Our finding that CD56
bright NK cells readily degranulate and
kill activated CD4
+ T cells has interesting therapeutic implications,
as NK cells with a CD56
bright phenotype have been implicated in
numerous autoimmune diseases. CD56
bright NK cells have been
associated with clinical remission in MS [15], and MS patients
responding to treatment with IFN-b showed an expansion in
CD56
bright NK cells and a concurrent reduction in CD4
+ and
CD8
+ T cells [16,17]. Furthermore, reduced brain inflammation
following treatment of MS patients with Daclizumab (an
antagonistic humanized mAb against the IL-2Ra chain) correlated
with an expansion of CD56
bright NK cells and a reduction in CD4
+
and CD8
+ T cells in vivo [61]. Similar results were found in patients
with autoimmune uveitis who were treated with Daclizumab [62].
In a study of relapsing-remitting (RR)-MS, a reduction in NK cell
functional activity correlated with the appearance of active lesions
and pre-ceded clinical attacks, suggesting that NK cells may play a
protective role in ongoing MS [63].
CD56
bright NK cells are found in abundance at inflammatory
sites in a number of diseases [12,13,64–67], and an important
question that arises is to what extent CD56
bright NK cells in blood
Figure 5. NK cells mediate TRAIL-dependent cytotoxicity towards activated CD4
+ T cells. Autologous NK cells and CD4
+ T cells were
isolated and activated for 4 days as described. Resting NK and CD4
+ T cells were unstimulated in media for 4 days. (A) Representative histograms for
flow cytometric analysis of surface expression of TRAIL-R1 (DR4) and TRAIL-R2 (DR5) on activated CD4
+ T cells (thick black line) and resting CD4
+ T
cells (thin black line). Isotype-matched control Ig are represented by dashed line (activated CD4
+ T) and filled histogram (resting CD4
+). (B) Histograms
are representative of TRAIL surface expression on activated NK cells (thick black line) and resting NK cells (thin black line). Isotype-matched control Ig
are represented by dashed line (activated NK) and filled histogram (resting NK). (C) Sorted IL-2-activated CD56
dim and CD56
bright NK cells were co-
cultured with
51Cr-labeled activated CD4
+ T cells in a
51Cr-release assay with isotype-matched control Ig (N) or anti-TRAIL mAb (#). Experiment
shown is representative of n=3.
doi:10.1371/journal.pone.0031959.g005
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bright NK cells found at inflammatory
sites. Phenotypical characterization of CD56
bright NK cells from
the synovial fluid of RA patients has shown that synovial fluid
CD56
bright NK cells share many features with CD56
bright NK cells
from the blood: they are NKG2A
+CD25
+KIR
2 and produce IFN-
c in response to low concentrations of cytokines [68]. In contrast
to CD56
bright NK cells in the blood, however, they are CD69
+ and
NKp44
+ and therefore have an activated phenotype, suggesting
local activation [69]. The accumulation of CD56
bright NK cells at
inflammatory sites may be due to preferential recruitment of this
subset from the blood, an idea that is supported by the finding that
CD56
bright NK cells in the blood constitutively express CCR5,
CCR7 and CD62L, which could regulate their recruitment to
inflammatory sites and lymphoid tissues [70,71]. CD56
bright NK
cells express CCR5, which potentially regulates their homing to
inflammatory sites in RA where high concentrations of MIP-1a,
MIP-1b and RANTES have been found [65]. It cannot be ruled
out that the presence of NK cells with a CD56
bright phenotype in
inflammatory sites might also be due to local proliferation or local
differentiation.
Our finding that both subsets of activated NK cells degranulate
in response to activated CD4
+ T cells, and use the same receptors
in doing so regardless of how they are activated, suggests that any
NK cell that receives activation signals that are sufficient to
overcome the threshold required for activation, has the potential
to kill a target cell. Enhancing NK cell-mediated clearance of
autoreactive CD4
+ T cells in chronic inflammation by masking an
inhibitory receptor such as NKG2A, therefore, presents an
interesting therapeutic possibility. Indeed, it has been shown in a
mouse model of MS, MOG-induced EAE, that administration of
an anti-NKG2A F(ab)’2 fragment results in potent NK cell-
mediated elimination of infiltrating pathogenic CD4
+ T cells and
microglia, and amelioration of EAE [9,10]. The advantage of this
approach is the specific targeting of activated, potentially
autoreactive, immune cells, and not healthy tissues. Further
studies are required to elucidate the mechanism of action of
immunoregulatory NK cells in chronic inflammation in vivo, and
how the cytotoxic potential of these regulatory immune cells can
be utilized to treat autoimmunity.
Materials and Methods
NK cell and CD4
+ T cell isolation and in vitro culture
Peripheral blood mononuclear cells (PBMC) were obtained
from Histopaque (Sigma-Aldrich) separation of buffy coats from
healthy donors supplied anonymously from the Clinical Immu-
nology Blood Bank, The State University Hospital, Copenhagen.
Some donors were healthy adult volunteers at UCSF whose
PBMC were obtained by density gradient centrifugation over
Ficoll-Paque (GE Healthcare). All volunteers gave informed
consent to participate in the study (approved by University of
California San Francisco Committee on Human Research IRB
10-00265). NK cells and CD4
+ T cells were isolated from PBMC
by negative selection using antibody-coated bead separation
(EasySep Enrichment Kits, StemCell Technologies) and cultured
for 4 days at 1610
6 cells/mL in RPMI-1640 GlutaMAX
TM
medium (Invitrogen) supplemented with 10% fetal calf serum and
1% penicillin and streptomycin. Cell purities were 95%–99%
(confirmed by flow cytometry). Isolated CD4
+ T cells were
activated with anti-CD3+anti-CD28 DynaBeads (Invitrogen) for 4
days; 10 mM sodium propionate (Sigma-Aldrich) was added for
the last 24 hours of culture. NK cells were cultured for 4 days in
media containing 200 U/mL recombinant human IL-2 (Proleu-
kin, Novartis). Alternatively, NK cells were stimulated with the
following recombinant human cytokines where indicated: 25 ng/
ml IL-7, IL-4, IL-9; 50 ug/mL IL-12, 0.25 mg/mL IL-18 (all from
R&D Systems); 100 ug/mL IL-21 (Miltenyi Biotec), 5 ug/mL IL-
15 (PeproTech), 100 U/mL IFN-aA (PBL InterferonSource).
After 4 days in culture, viability of NK and CD4
+ T cells (both
resting and activated) was typically more than 90%. For some
experiments, NK cells were isolated from PBMC using antibody-
coated bead separation (Miltenyi Biotec).
Cytotoxicity assays
Following 4 days of activation, autologous NK cells and CD4
+
T cells were co-cultured at an effector:target (E:T) ratio of 1:1 for
4 hours at 37uC with FITC-conjugated anti-CD107a mAb (H4A3,
BD Biosciences), FITC-conjugated anti-CD107b mAb (H4B4, BD
Biosciences) and GolgiStop
TM containing monensin (BD Biosci-
ences). The following anti-human mAbs were added at 10 ug/mL
where indicated: NKG2D (149810, R&D Systems), NKG2A
(NNC0141-0100, Novo Nordisk A/S), LIR-1 (GHI/75, BioLe-
gend), 2B4 (C1.7, BioLegend), DNAM-1 (DX11, BioLegend),
NKp30 (P30-15, BioLegend), NKp44 (P44-8, BioLegend), NKp46
(9E2, BioLegend), LFA-1/CD11a (HI111, BioLegend), TRAIL
(RIK-2, BioLegend), TIGIT (MBSA43, eBioscience) and CD96
(NK92.39, BioLegend). Mouse IgG1 (R&D Systems) and human
IgG4 (Sigma-Aldrich) were used as isotype-matched Ig controls.
None of the antibodies resulted in CD107a/b expression on the
cell surface when added to NK cells alone. For
51Cr-release assays,
CD4
+ T cells were labeled with Na
51Cr04 (Amersham Bioscienc-
es). NK cells were added at effector:target (E:T) ratios from 40:1 to
0.625:1 in duplicates. Cells were incubated for 5 hours at 37uC,
and released
51Cr was measured in a TopCount (PerkinElmer).
Spontaneous lysis was determined by incubating target cells alone,
and maximum lysis was determined by the addition of 10% Triton
X-100 in PBS to target cells. Percentage specific lysis=(experi-
mental
51Cr release2spontaneous
51Cr release)/(maximum
51Cr
release2spontaneous
51Cr release)6100.
Flow cytometry
Following the 4-hour cytotoxicity assay, cells were stained with
PerCP-conjugated anti-CD3 (SK7, BD Biosciences), PerCP-
conjugated anti-CD4 (11830, R&D Systems), Pacific Blue-
conjugated anti-CD16 (3G8, BD Biosciences), PE-conjugated
anti-NKG2A (Z199, Beckman Coulter), Alexa Fluor 700-conju-
gated anti-CD56 (B159, BD Biosciences) and Near-IR LIVE/
DEADH Fixable Dead Cell Stain (Invitrogen). NK cells were gated
as viable, CD3
2CD4
2 cells and NK cell subsets were defined
based on expression of CD56 and CD16.
CD4
+ T cells were surface stained for the presence of antigens
with the following antibodies at 10 ug/mL or 1:100 dilution: anti-
HLA-E (3D12HLA-E, eBioscience), anti-MHC class I (DX17, BD
Biosciences), PE-conjugated anti-CD48 (BJ40, BioLegend), anti-
MIC-A (159213), anti-MIC-B (236511), anti-ULBP-1 (170818,
R&D Systems), anti-ULBP-2 (165903, R&D Systems), anti-ULBP-
3 (166510, R&D Systems), anti-CD112 (R2.525, BD Biosciences),
PE-conjugated anti-CD155 (SKII.4, BioLegend), APC-conjugated
anti-CD54 (HA58, BD Biosciences), anti-TRAIL-R1 (DJR1,
BioLegend) and anti-TRAIL-R2 (DJR2-4(7-8), BioLegend). Un-
conjugated antibodies were detected by subsequent incubation
with APC-conjugated donkey anti-mouse IgG (Jackson Immu-
noResearch). Mouse IgG1, mouse IgG2a and mouse IgG2b were
used as isotype-matched controls (R&D Systems). CD4
+ T cells
were stained with Pacific Blue-conjugated anti-CD3 (OKT3,
eBioscience), Alexa Fluor 700-conjugated anti-CD4 (BioLegend),
PerCP-conjugated anti-CD8 (SK1, BD Biosciences) and Near-IR
LIVE/DEADH Fixable Dead Cell Stain (Invitrogen). CD4
+ T cells
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+CD4
+CD8
2 cells. All flow cytometry
was carried out using a BD LSR II flow cytometer.
Statistical analysis
Statistical significances were determined by using the paired,
two-tailed Student’s t-test, or a two-way ANOVA. All calculated
averages were defined as parametric mean 6 SEM. Statisti-
cal significance is defined as the following: * P,0.05; ** P,0.01;
*** P,0.001. Statistics were determined with GraphPad Prism
Software.
Supporting Information
Figure S1 Representative gating strategy used to define
CD56
dim and CD56
bright NK cells.
(TIFF)
Figure S2 CD96, TIGIT, NKp30, NKp44, 2B4 and LIR-1
are not involved in NK cell killing. (A, C) Left column:
representative histograms for surface expression of ligands on
activated (thick black line) and resting CD4
+ T cells (thin black
line). Isotype-matched control Ig are represented by dashed line
(activated CD4
+ T) and filled histogram (resting CD4
+). Flow
cytometry was performed to assess degranulation of CD56
dim
(middle column) and CD56
bright (right column) NK cells.
Representative histograms show surface expression of receptors
on activated NK cells (thick black line) and resting NK cells (thin
black line). Isotype-matched control Ig are represented by dashed
line (activated NK) and filled histogram (resting NK). * P,0.05 (B)
Sorted IL-2-activated CD56
dim and CD56
bright NK cells were co-
cultured with
51Cr-labeled activated CD4
+ T cells in a
51Cr-
release assay, with relevant isotype-matched control Ig or anti-2B4
mAb.
(TIFF)
Figure S3 CD4
+ T cell expression of HLA class I.
Representative histograms for surface expression of HLA class I
on activated (thick black line) and resting CD4
+ T cells (thin black
line). Isotype-matched control Ig are represented by dashed line
(activated CD4
+ T) and filled histogram (resting CD4
+).
(TIFF)
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